Navigation Links
Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
Date:9/5/2007

Barcelona Hosts Key Investigator Meeting for European Participants in Phase

3 AGENDA Trial Targeting Biomarker-Defined Population

BERKELEY HEIGHTS, N.J., Sept. 5 /PRNewswire-FirstCall/ - Genta Incorporated (Nasdaq: GNTA) announced that data from the Company's Phase 3 trial of Genasense(R) (oblimersen sodium) plus chemotherapy would be presented at the opening session of the first Worldwide Melanoma Center Meeting organized by the European Association of Dermato-Oncology (EADO). Genta, which is a Silver Level sponsor of the EADO meeting, will also host its key investigator meeting for European participants in the Company's ongoing Phase 3 trial of Genasense in advanced melanoma. The Genasense clinical results will be presented by Dr. Claus Garbe, who is Chair of the Congress, and Professor of Dermatology and Head of the Division of Dermatooncology, Department of Dermatology, University Medical Center, Tubingen, Germany. The EADO, which is the lead international cooperative group for the current Phase 3 trial, is meeting this week in Barcelona, Spain.

The new Genasense trial, known as AGENDA, is a randomized, double-blind, placebo-controlled study in which patients are randomly assigned to receive Genasense plus dacarbazine (DTIC) or DTIC alone. AGENDA is designed to confirm the safety and efficacy of Genasense when combined with DTIC in patients who have not previously received chemotherapy. The trial will accrue approximately 300 patients who have been defined using a biomarker and will be conducted at approximately 100 sites worldwide, including North America, Europe and Australia. Patient enrollment into AGENDA has been initiated.

About Genasense in Advanced Melanoma

Genasense, Gent
'/>"/>

SOURCE Genta Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. IDM Pharma Presents Preliminary Results from Phase II UVIDEM Melanoma Vaccine Clinical Trial
2. Synta Presents Results for STA-4783 in Metastatic Melanoma Showing Improvement in Overall Survival
3. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
4. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
5. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
6. SciClone and Sigma-Tau Report Thymalfasin Meets Primary Endpoint in Phase 2 Malignant Melanoma Trial
7. Inovio Biomedicals DNA Delivery Technology Shows Safety and Enhances Gene Expression & Tumor Responses in Interim Melanoma Clinical Study Results
8. Multiferon Shows Potent Activity in Preventing the Progression of Malignant Melanoma; Study to be Published
9. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
10. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
11. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... Wash. , May 22, 2015  BioLife Solutions, Inc. ... of proprietary clinical grade hypothermic storage and ... for cells and tissues ("BioLife" or the "Company"), announced ... Marcum MicroCap Conference. The Company is scheduled ... Wednesday, May 27, 2015 at the Grand Hyatt Hotel in ...
(Date:5/22/2015)... May 22, 2015 The leading companies ... billion global cardiac rhythm management device market dominate ... that Medtronic, St. Jude Medical, Boston Scientific and ... this market segment. The healthcare market research publisher,s ... uses 2015 as a base year, providing forecasts ...
(Date:5/22/2015)... 22, 2015  The U.S. Food and Drug ... the first biosimilar product approved in ... growth in the contract manufacturing organization (CMO) industry, ... is geared to the production of small-molecular drugs ... products. The healthcare market research publisher,s report, ...
Breaking Medicine Technology:BioLife Solutions To Present At The 2015 Marcum MicroCap Conference In New York City 2Kalorama: Top Companies Dominate Cardiac Defibrillator Market 2Kalorama: Top Companies Dominate Cardiac Defibrillator Market 3Kalorama: Top Companies Dominate Cardiac Defibrillator Market 4Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 4
... Odyssey Thera, Inc. announced today that the United ... No. 7,855,167.  The invention describes technologies and high-throughput ... based on protein-fragment complementation assays (PCA).  The ... protects assays utilizing fragments of inherently fluorescent proteins, ...
... N.J., Jan. 5, 2011 Amicus Therapeutics (Nasdaq: ... John F. Crowley will be presenting a business update and ... at the upcoming 29th Annual J.P. Morgan Healthcare Conference.  Mr. ... at 3:00 p.m. PST. Individuals can listen to ...
Cached Medicine Technology:
(Date:5/25/2015)... Henderson, NV (PRWEB) May 25, 2015 ... this year, the radical science-based human wellness company ... one-day workshop event from their world-class series titled, “Consciousness ... be held on June 13, 2015 at the routinely ... pm EST. The event will be made available to ...
(Date:5/25/2015)... Burke Rehabilitation Hospital will welcome Samuel White, ... City, to speak at Burke on Wednesday, June 3. The ... Lecture series, will take place at 4:30 p.m. on Burke’s ... of Stanford White of McKim, Mead and White, the famed ... years ago. , “We are thrilled to welcome Samuel White ...
(Date:5/24/2015)... 25, 2015 Pacific Prime has announced that they ... looking at the cost of individual international health insurance. Titled: ... looks at the cost of health insurance in six top expat ... Hong Kong , Singapore , ... UAE , the UK , Article 2 ...
(Date:5/24/2015)... Clarkston, Metamora, Michigan (PRWEB) May 24, 2015 ... patients for concerns about hair loss. Although it is ... clear that there are environmental factors such as metabolism, ... can contribute. Since they offer a comprehensive approach to ... peri and post-menopausal woman, they can help patients find ...
(Date:5/24/2015)... Birmingham, Lake Orion, Clarkston, Metamora, Michigan (PRWEB) May 24, ... urodynamic tests, which will allow them to take pressure ... information about bladder function. The doctor usually orders it ... (SUI) or overactive bladder (OAB). , Women’s ... women that have problems with unwanted urinary leakage or ...
Breaking Medicine News(10 mins):Health News:Hundreds of People Are Thrilled to Hear that Trivedi Master Wellness™ Promises to Hold Another Workshop in June 2015 2Health News:Hundreds of People Are Thrilled to Hear that Trivedi Master Wellness™ Promises to Hold Another Workshop in June 2015 3Health News:Burke Rehabilitation Hospital Welcomes Architect Samuel White, Descendant of McKim, Mead and White, for Legacy Lobby Lecture 2Health News:Burke Rehabilitation Hospital Welcomes Architect Samuel White, Descendant of McKim, Mead and White, for Legacy Lobby Lecture 3Health News:Pacific Prime Releases 2nd Article of Cost of Health Insurance Report 2Health News:Women's Excellence Now Treats Menopausal Hair Loss 2
... June 15 (HealthDay News) -- Most working fathers say they ... a lot of them admit that they aren,t actually doing ... many dads are conflicted about finding a work-family balance, according ... Family. The survey of nearly 1,000 American fathers with ...
... study by the University of California, San Francisco,s Cardiac Electrophysiology ... causes of sudden cardiac death (SCD), why it is more ... often inaccurately cited as a cause of death. Working ... City and County of San Francisco, researchers will fully investigate ...
... -- Weight loss surgery patients who are discharged from the ... risk of complications and death, a new study has found. ... patients, researchers found that those released from the hospital the ... serious complications (1.9 percent versus 0.16 percent) and 13 times ...
... IOF Regionals 1st Middle-East & Africa Osteoporosis Meeting, ... has published its scientific programme at , http://www.iofbonehealth.org/dubai-2011/programme.html ... is offering awards of 1000 USD each for the ... of age. The abstract deadline is June 17, 2011; ...
... On June 21-23, 2011, the New York Academy ... neuropsychologists, cellular and molecular biologists and patient advocates ... improving diagnosis, treatment and management of the cognitive ... conference titled "Cognitive Dysfunction in Multiple Sclerosis: New ...
... , New York, NY, June 15, 2011A new Commonwealth ... are owned by publicly traded for-profit companies whose primary ... average of 14 percent of premiums on administrative costs, ... by non-publicly traded plans owned by groups of health ...
Cached Medicine News:Health News:Sudden cardiac death subject of sweeping UCSF study in San Francisco 2Health News:Sudden cardiac death subject of sweeping UCSF study in San Francisco 3Health News:Rushed Discharge After Weight-Loss Surgery May Raise Risks 2Health News:Program announced for 1st Middle-East & Africa Osteoporosis Meeting 2Health News:The New York Academy of Sciences to host a symposium on cognitive dysfunction in multiple sclerosis 2Health News:Medicaid managed care plans owned by public companies have higher administrative costs 2Health News:Medicaid managed care plans owned by public companies have higher administrative costs 3
The 9114-3.5 transducer is a versatile general imaging transducer. With multifrequencies, this transducer provides superb image quality and meets a multitude of imaging needs....
The versatility of multiple imaging frequencies and a smaller transducer face make this transducer is perfect for intercostal imaging....
... XL3000 by PerkinElmer,is a complete ... in,Cermax Xenon technology.,Cermax Xenon is ... integration into endoscopy,equipment and other ... color illumination.,It provides many advantages ...
... 350 Chemistry System offers easy operation, maintenance, and ... STAT, or back-up to the powerful VITROS 5,1 ... the job done right the first time. Its ... are efficient, dependable, and easy-to-use. The VITROS 350 ...
Medicine Products: